881391-36-2Relevant academic research and scientific papers
Discovery and Structure-Activity Relationships of Nociceptin Receptor Partial Agonists That Afford Symptom Ablation in Parkinson's Disease Models
Kamakolanu, Uma Gayathri,Meyer, Michael E.,Yasuda, Dennis,Polgar, Willma E.,Marti, Matteo,Mercatelli, Daniela,Pisanò, Clarissa Anna,Brugnoli, Alberto,Morari, Michele,Zaveri, Nurulain T.
, p. 2688 - 2704 (2020/03/31)
A novel series of C(3)-substituted piperdinylindoles were developed as nociceptin opioid receptor (NOP) partial agonists to explore a pharmacological hypothesis that NOP partial agonists would afford a dual pharmacological action of attenuating Parkinson'
PIPERDINYL NOCICEPTIN RECEPTOR COMPOUNDS
-
Paragraph 0147-0149; 0158, (2018/06/15)
The present invention provides novel piperidinyl-containing nociceptin receptor ligand compounds and pharmaceutical compositions useful in the treatment of neurological diseases and conditions where such ligands mediate the negative effects of the condition. Such neurological diseases and conditions include acute and chronic pain, substance abuse/dependence, alcohol addiction, anxiety, depression, sleep disorders, gastrointestinal disorders, renal disorders, cardiovascular disorders and Parkinson's disease.
PIPERIDINYL NOCICEPTIN RECEPTOR COMPOUNDS
-
Page/Page column 101; 102; 105; 106, (2017/12/28)
The present invention provides novel piperidinyl-containing nociceptin receptor ligand compounds and pharmaceutical compositions useful in the treatment of neurological diseases and conditions where such ligands mediate the negative effects of the condition. Such neurological diseases and conditions include acute and chronic pain, substance abuse/dependence, alcohol addiction, anxiety, depression, sleep disorders, gastrointestinal disorders, renal disorders, cardiovascular disorders and Parkinson' s disease.
HETEROCYCLIC DERIVATIVES AND THEIR USE AS MEDIATORS OF STEAROYL-COA DESATURASE
-
Page/Page column 43-44, (2010/10/20)
Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): Formula (I) where x, y, G, J, L, M, V, W, R2, R3, R4, R5, R5a, R6, R6a, R7, R7a, R8 and R8a are defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed.
